- Home
- AMST vs MYNZ Comparison
AMST vs MYNZ Comparison
Compare AMST & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- MYNZ
- Stock Information
- Founded
- AMST 2017
- MYNZ 2021
- Country
- AMST United States
- MYNZ Germany
- Employees
- AMST N/A
- MYNZ N/A
- Industry
- AMST Computer Software: Prepackaged Software
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- MYNZ Health Care
- Exchange
- AMST Nasdaq
- MYNZ Nasdaq
- Market Cap
- AMST 7.4M
- MYNZ 7.2M
- IPO Year
- AMST 2020
- MYNZ 2021
- Fundamental
- Price
- AMST $2.13
- MYNZ $3.20
- Analyst Decision
- AMST
- MYNZ Buy
- Analyst Count
- AMST 0
- MYNZ 2
- Target Price
- AMST N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- AMST 56.4K
- MYNZ 105.1K
- Earning Date
- AMST 05-09-2025
- MYNZ 05-06-2025
- Dividend Yield
- AMST N/A
- MYNZ N/A
- EPS Growth
- AMST N/A
- MYNZ N/A
- EPS
- AMST N/A
- MYNZ N/A
- Revenue
- AMST $86,115.00
- MYNZ $893,991.00
- Revenue This Year
- AMST N/A
- MYNZ $42.95
- Revenue Next Year
- AMST N/A
- MYNZ N/A
- P/E Ratio
- AMST N/A
- MYNZ N/A
- Revenue Growth
- AMST N/A
- MYNZ N/A
- 52 Week Low
- AMST $2.00
- MYNZ $0.18
- 52 Week High
- AMST $6.27
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- AMST 43.60
- MYNZ 40.90
- Support Level
- AMST $2.00
- MYNZ $3.03
- Resistance Level
- AMST $2.23
- MYNZ $3.31
- Average True Range (ATR)
- AMST 0.19
- MYNZ 0.35
- MACD
- AMST 0.01
- MYNZ 0.06
- Stochastic Oscillator
- AMST 25.00
- MYNZ 61.80
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.